<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35244521</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1744-5116</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>60</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pharmaceutical biology</Title>
          <ISOAbbreviation>Pharm Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Injection of YiQiFuMai powder protects against heart failure via inhibiting p38 and ERK1/2 MAPKs activation.</ArticleTitle>
        <Pagination>
          <StartPage>570</StartPage>
          <EndPage>578</EndPage>
          <MedlinePgn>570-578</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/13880209.2022.2038207</ELocationID>
        <Abstract>
          <AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Injection of YiQiFuMai (YQFM) powder, a modern Chinese plant-derived medical preparation, has a therapeutic effect in heart failure (HF). However, its therapeutic mechanism remains largely unknown.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the molecular mechanisms of YQFM in HF.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Kinase inhibition profiling assays with 2 mg/mL YQFM were performed against a series of 408 kinases. In addition, the effects of kinase inhibition were validated in cardiomyocyte cell line H9c2. <i>In vivo</i>, HF with reduced ejection fraction (HFrEF) was induced by permanent left anterior descending (LAD) coronary artery ligation for 6 weeks in male Sprague-Dawley rats. Then, HFrEF mice were treated with 0.46 g/kg YQFM or placebo once a day for 2 weeks. Echocardiography, immunohistochemistry, histological staining and Western blotting analysis were performed to assess the myocardial damage and molecular mechanisms.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Kinase inhibition profiling analysis demonstrated that mitogen-activated protein kinases (MAPKs) mediated the signalling cascades of YQFM during HF therapy. Meanwhile, p38 and extracellular signal-regulated kinases (ERK1/2) were inhibited after YQFM treatment in H9c2 cells. In rats, the control group had lower left ventricular ejection fraction (LVEF) at 37 ± 1.7% compared with the YQFM group at 54 ± 1.1% (<i>p</i> &lt; 0.0001). Cardiac fibrosis levels in control group rats were significantly higher than YQFM group (30.5 ± 3.0 vs. 14.1 ± 1.0, <i>p</i> &lt; 0.0001).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our collective <i>in vitro</i> and <i>in vivo</i> experiments demonstrated that YQFM improves left ventricular (LV) function and inhibits fibrosis in HFrEF rats by inhibiting MAPK signalling pathways.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nie</LastName>
            <ForeName>Yongwei</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-4553-4474</Identifier>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Nankai University, Tianjin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yanxin</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Tianjin Tasly Pride Pharmaceutical Co., Ltd., Tianjin, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Tianjin Key Laboratory of Safety Evaluation Enterprise of TCM Injections, Tianjin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Zhi</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Tianjin Tasly Pride Pharmaceutical Co., Ltd., Tianjin, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Tianjin Key Laboratory of Safety Evaluation Enterprise of TCM Injections, Tianjin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wan</LastName>
            <ForeName>Meixu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Tianjin Tasly Pride Pharmaceutical Co., Ltd., Tianjin, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Tianjin Key Laboratory of Safety Evaluation Enterprise of TCM Injections, Tianjin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Dekun</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Tianjin Tasly Pride Pharmaceutical Co., Ltd., Tianjin, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Tianjin Key Laboratory of Safety Evaluation Enterprise of TCM Injections, Tianjin, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Pharm Biol</MedlineTA>
        <NlmUniqueID>9812552</NlmUniqueID>
        <ISSNLinking>1388-0209</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002316">Cardiotonic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C584693">yi-qi-fu-mai</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002316" MajorTopicYN="N">Cardiotonic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016277" MajorTopicYN="N">Ventricular Function, Left</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048051" MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Traditional Chinese Medicine</Keyword>
        <Keyword MajorTopicYN="N">cardiac fibrosis</Keyword>
        <Keyword MajorTopicYN="N">kinase inhibition</Keyword>
      </KeywordList>
      <CoiStatement>We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>12</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35244521</ArticleId>
        <ArticleId IdType="pmc">PMC8903779</ArticleId>
        <ArticleId IdType="doi">10.1080/13880209.2022.2038207</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ai F, Guo QH, Yu B, Li W, Guo X, Chen Z.. 
2019. Schisandrin B attenuates pressure overload-induced cardiac remodeling in mice by inhibiting the MAPK signaling pathway. Exp Ther Med. 18(6):4645–4652.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6878904</ArticleId>
            <ArticleId IdType="pubmed">31798701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arabacilar P, Marber M.. 
2015. The case for inhibiting p38 mitogen-activated protein kinase in heart failure. Front Pharmacol. 6:102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4428223</ArticleId>
            <ArticleId IdType="pubmed">26029107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Callender T, Woodward M, Roth G, Farzadfar F, Lemarie JC, Gicquel S, Atherton J, Rahimzadeh S, Ghaziani M, Shaikh M, et al. . 
2014. Heart failure care in low- and middle-income countries: a systematic review and meta-analysis. PLOS Med. 11(8):e1001699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4130667</ArticleId>
            <ArticleId IdType="pubmed">25117081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cook C, Cole G, Asaria P, Jabbour R, Francis DP.. 
2014. The annual global economic burden of heart failure. Int J Cardiol. 171(3):368–376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24398230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esposito G, Prasad SV, Rapacciuolo A, Mao L, Koch WJ, Rockman HA.. 
2001. Cardiac overexpression of a g(q) inhibitor blocks induction of extracellular signal-regulated kinase and c-jun nh(2)-terminal kinase activity in in vivo pressure overload. Circulation. 103(10):1453–1458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11245652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng YQ, Ju AC, Liu CH, Wang T, Yu BY, Qi J.. 
2016. Protective effect of the extract of Yi-Qi-Fu-Mai preparation on hypoxia-induced heart injury in mice. Chin J Nat Med. 14(6):401–406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27473956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Figtree GA, Broadfoot K, Casadei B, Califf R, Crea F, Drummond GR, Freedman JE, Guzik TJ, Harrison D, Hausenloy DJ, et al. . 
2021. A call to action for new global approaches to cardiovascular disease drug solutions. Eur Heart J. 42(15):1464–1475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33847746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Gwathmey J, Grazette L, Michael A, Hajjar R, Force T, et al. . 
2001. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation. 103(5):670–677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11156878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, et al. . 
2013. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 6(3):606–619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3908895</ArticleId>
            <ArticleId IdType="pubmed">23616602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karmazyn M, Moey M, Gan XT.. 
2011. Therapeutic potential of ginseng in the management of cardiovascular disorders. Drugs. 71(15):1989–2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21985167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumphune S, Surinkaew S, Chattipakorn SC, Chattipakorn N.. 
2015. Inhibition of p38 MAPK activation protects cardiac mitochondria from ischemia/reperfusion injury. Pharm Biol. 53(12):1831–1841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25880145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li F, Zheng X, Fan X, Zhai K, Tan Y, Kou J, Yu B.. 
2016. YiQiFuMai powder injection attenuates ischemia/reperfusion-induced myocardial apoptosis through AMPK activation. Rejuvenation Res. 19(6):495–508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27072567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao P, Wang SQ, Wang S, Zheng M, Zheng M, Zhang SJ, Cheng H, Wang Y, Xiao R-P.. 
2002. P38 mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ Res. 90(2):190–196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3705214</ArticleId>
            <ArticleId IdType="pubmed">11834712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molkentin JD, Bugg D, Ghearing N, Dorn LE, Kim P, Sargent MA, Gunaje J, Otsu K, Davis J.. 
2017. Fibroblast-specific genetic manipulation of p38 mitogen-activated protein kinase in vivo reveals its central regulatory role in fibrosis. Circulation. 136(6):549–561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5548661</ArticleId>
            <ArticleId IdType="pubmed">28356446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nie H, Li S, Liu M, Zhu W, Zhou X, Yan D.. 
2020. Yiqi Fumai injection as an adjuvant therapy in treating chronic heart failure: a meta-analysis of 33 randomized controlled trials. Evid Based Complement Alternat Med. 2020:1876080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7453275</ArticleId>
            <ArticleId IdType="pubmed">32922505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nie Y, Liu D.. 
2017. N-Glycosylation is required for FDNC5 stabilization and irisin secretion. Biochem J. 474(18):3167–3177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28733331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nie YW, Wang M, Zhang P, Huan L, Liu DJ.. 
2016. Identification and characterization of an endoplasmic reticulum localization motif. Biochem Biophys Res Commun. 473(1):249–254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27005820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Owens AT, Jessup M.. 
2011. The year in heart failure. J Am Coll Cardiol. 57(15):1573–1583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21474036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pang LZ, Ju AC, Zheng XJ, Li F, Song YF, Zhao Y, Gu YF, Chen FL, Liu CH, Qi J, et al. . 
2017. YiQiFuMai powder injection attenuates coronary artery ligation-induced myocardial remodeling and heart failure through modulating MAPKs signaling pathway. J Ethnopharmacol. 202:67–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28237302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, et al. . 
2014. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 1(1):4–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28834669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shabu S, Jayasekara R.. 
2020. Effectiveness of cognitive behavior therapy for patients with heart failure and depression: a systematic review protocol. Nurs Health Sci. 22(1):14–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31499596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Triposkiadis F, Giamouzis G, Parissis J, Starling RC, Boudoulas H, Skoularigis J, Butler J, Filippatos G.. 
2016. Reframing the association and significance of co-morbidities in heart failure. Eur J Heart Fail. 18(7):744–758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27358242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woulfe KC, Travers JG, McKinsey TA.. 
2020. A phosphatase anchor weighs on the heart. Circulation. 142(10):963–966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8496970</ArticleId>
            <ArticleId IdType="pubmed">32897751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xing L, Jiang M, Dong L, Gao J, Hou Y, Bai G, Luo G.. 
2013. Cardioprotective effects of the YiQiFuMai injection and isolated compounds on attenuating chronic heart failure via NF-κB inactivation and cytokine suppression. J Ethnopharmacol. 148(1):239–245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23619019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yokota T, Li J, Huang J, Xiong Z, Zhang Q, Chan T, Ding Y, Rau C, Sung K, Ren S, et al. . 
2020. P38 mitogen-activated protein kinase regulates chamber-specific perinatal growth in heart. J Clin Invest. 130(10):5287–5301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7524480</ArticleId>
            <ArticleId IdType="pubmed">32573492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan Q, Wang J, Fang QH, Liu YY, Fan JY, Zhang SW, Ma YM.. 
2011. Attenuating effect of pretreatment with YiQiFuMai on lipopolysaccharide-induced intestine injury and survival rate in rat. J Inflamm. 8:10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3095532</ArticleId>
            <ArticleId IdType="pubmed">21535877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Fan S, Mao Y, Ji Y, Jin L, Lu J, Chen X.. 
2016. Cardiovascular protective effect of polysaccharide from Ophiopogon japonicus in diabetic rats. Int J Biol Macromol. 82:505–513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26434529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Zhao Y, Bai D, Yuan X, Cong S.. 
2019a. Schizandrin protects H9c2 cells against lipopolysaccharide-induced injury by downregulating smad3. J Biochem Mol Toxicol. 33(5):e22301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30801894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Zhang L, Zhang Y, Fan X, Yang W, Yu B, Kou J, Li F.. 
2019b. YiQiFuMai powder injection attenuates coronary artery ligation-induced heart failure through improving mitochondrial function via regulating ROS generation and CaMKII signaling pathways. Front Pharmacol. 10:381.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6470332</ArticleId>
            <ArticleId IdType="pubmed">31031629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao D, Liu J, Xie W, Qi Y.. 
2015. Cardiovascular risk assessment: a global perspective. Nat Rev Cardiol. 12(5):301–311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25754885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou D, Tong L, Wan M, Wang G, Ye Z, Wang Z, Lin R.. 
2011. An LC–MS method for simultaneous determination of nine ginsenosides in rat plasma and its application in pharmacokinetic study. Biomed Chromatogr. 25(6):720–726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20812205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ziaeian B, Fonarow GC.. 
2016. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 13(6):368–378.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4868779</ArticleId>
            <ArticleId IdType="pubmed">26935038</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
